98%
921
2 minutes
20
Background: Individuals with hypertension and hyperuricemia have an increased risk of coronary artery disease and cerebral vascular disease as compared to patients with normal uric acid levels. Our aim is to determine the prevalence of hyperuricemia in hypertensive patients in Taiwan, and whether serum uric acid (SUA) is associated with changes in renal function in patients with hypertension.
Methods: We studied 2145 hypertensive patients receiving medical treatment, assessed the prevalence of hyperuricemia, and determined the independent risk factors for SUA. Simple correlation and multiple regression analyses were applied to identify the independent risk factors for SUA increase. Logistic regression analysis was used to estimate the association between 4 quartiles of SUA level and correspondent serum creatinine (SCr) concentrations.
Results: Hypertensive subjects had a high prevalence of hyperuricemia (men, 35%; women, 43%). SUA was significantly associated with the independent risk factors of SCr, diuretic usage, and diabetes (inversely related) in both genders, whereas β-blocker usage and body mass index were only associated in men. Multiple logistic regression models showed that in the non-diuretic user group the highest SUA quartile entailed >4 times greater risk for SCr elevation than the lowest. In the diuretic user group, a >2 times greater risk was noted.
Conclusions: Hyperuricemia hypertensive subjects demonstrated a corresponding elevation of SUA and SCr irrespective of diuretic use. Elevation of SUA, in addition to SCr, may represent a progression of renal function impairment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijcard.2009.11.024 | DOI Listing |
Kardiologiia
September 2025
Department of Cardiology, The Ninth Medical Center, Chinese PLA General Hospital.
Background Hyperuricemia (HUA) frequently coexists with coronary artery disease (CAD) and is linked to adverse cardiovascular outcomes. The long-term impact of urate-lowering therapy (ULT) on clinical outcomes, including all-cause mortality and major adverse cardiovascular events (MACEs), in CAD patients after percutaneous coronary intervention (PCI) has not been determined. That was the aim of this study.
View Article and Find Full Text PDFClin Kidney J
September 2025
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Background: This study aimed to evaluate the efficacy and safety of telitacicept versus mycophenolate mofetil (MMF) in high-risk progressive immunoglobulin A nephropathy (IgAN).
Methods: This retrospective, multicentre cohort study included patients with high-risk progressive IgAN who received telitacicept or MMF therapy, both combined with low-dose steroids. Clinical data were collected from treatment initiation to 12 months.
Nutr Metab Cardiovasc Dis
July 2025
Department of Gastroenterology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315040, PR China. Electronic address:
Background And Aims: Obesity-related non-alcoholic fatty liver disease (NAFLD) and serum high-sensitivity C-reactive protein (hs-CRP) are known to be associated to some extent. Nevertheless, this relationship remains unclear in non-obese individuals.
Methods And Results: A prospective cohort study was conducted using data from the health check ups of employees at Zhenhai Refining and Chemical Hospital in Ningbo City.
J Clin Neurosci
September 2025
Azienda Sanitaria Provinciale Catania, Catania, Italy. Electronic address:
J Appl Lab Med
September 2025
Department of Pathology, UC San Diego Health, San Diego, CA, United States.
Background: While clinical laboratories routinely perform automated chemistry assays on approved specimens (e.g., plasma and serum), the FDA has not evaluated the validity of these assays for nonapproved specimens (e.
View Article and Find Full Text PDF